Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

We conducted a phase II study in patients with HER2-positive locally advanced breast cancer or pathologic stage 3 breast cancer. Patients received epirubicin with cyclophosphamide followed by docetaxel. Targeted therapy with trastuzumab and bevacizumab were administered for 1 year. The pathologic co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical breast cancer 2017-02, Vol.17 (1), p.48-54.e3
Hauptverfasser:	Smith, John W., Buyse, Marc E., Rastogi, Priya, Geyer, Charles E., Jacobs, Samuel A., Patocskai, Erica J., Robidoux, André, Conlin, Alison K., Ansari, Bilal, Keogh, George P., Stella, Philip J., Gross, Howard M., Lord, Raymond S., Polikoff, Jonathan A., Mauquoi, Celine, Mamounas, Eleftherios P., Swain, Sandra M., Wolmark, Norman
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Biomarkers, Tumor - metabolism Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Chemotherapy, Adjuvant Cohort Studies Cyclophosphamide - administration & dosage Epirubicin - administration & dosage Female Fluorouracil - administration & dosage Follow-Up Studies Humans Immunoenzyme Techniques Middle Aged Neoadjuvant chemotherapy Neoadjuvant Therapy Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - pathology Neoplasm Staging Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Survival Rate Taxoids - administration & dosage Trastuzumab - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!